Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

By afschroeder • July 2, 2025

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification. Dermatol Ther (Heidelb). 2025 Jul 2. doi: 10.1007/s13555-025-01474-3. Epub ahead of print. PMID: 40593269.

Tags: CorEvitas Psoriasis Registry, Dermatology, International Psoriasis Council disease reclassification, National Psoriasis Foundation treat-to-target goals, patient-reported outcomes, psoriasis, Publications, real-world, risankizumab, Skin clearance, Systemic-eligible

Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma

Robatel S, Hillen H, Mutisheva I, Müller JC, Wartenberg M, Ma F, Bäriswyl L, Evenepoel J, Scheele CLGJ, Lee DJ, Modlin RL, Kessler U, Nobis[...]

Association between out-of-pocket costs and treatment patterns in psoriasis and psoriatic arthritis: A claims-based cohort study

Roberts AM, Jeong C, Chou P, Ma EJ, Katz A, Yan MJ, Johnsen N, Nong Y, Armstrong AW. Association between out-of-pocket costs and treatment patterns[...]

Central centrifugal cicatricial alopecia is associated with longer time to diagnosis among scarring alopecias

Issa T, Klomhaus AM, Kasakevich C, Pickford J, Goh C. Central centrifugal cicatricial alopecia is associated with longer time to diagnosis among scarring alopecias. JAAD[...]